← Back to all trials
Recruiting
NCT06312683
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Conditions: Pouchitis
Sex: All
Ages: 18 Years – 74 Years
Healthy volunteers: No
Phase: PHASE4
Enrollment: 16
Sponsor: University of North Carolina, Chapel Hill
Location: NYU IBD Center New York New York
Summary
Although many people will develop recurrent pouchitis (inflammation of the ileal pouch-anal anastomosis or J-pouch after colectomy for ulcerative colitis) after an initial episode of pouchitis, there are currently no effective treatments to prevent recurrent pouchitis. The goal of this study is to evaluate the potential for rifaximin, an antibiotic, to prevent recurrent pouchitis after treatment for an initial episode of pouchitis. In this study, all patients will be given daily rifaximin for one year after being treated for an initial episode of pouchitis. This study will examine whether people are willing to take rifaximin for one year with the goal of preventing recurrent pouchitis. Additionally, this study will examine whether patients experience any unexpected side effects of rifaximin therapy. The information gained through this study will potentially be helpful in improving the ability to prevent recurrent pouchitis in patients who have a colectomy for ulcerative colitis.
Eligibility Criteria
Inclusion Criteria:
* Informed consent will be obtained before any study-related procedures
* Age \> 18 and \
Source: ClinicalTrials.gov (NCT06312683). StuddyBuddy aggregates publicly available trial information.